ArticleScientific reports2016
Modified serpinA1 as risk marker for Parkinson's disease dementia: Analysis of baseline data.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- Spatial transcriptome analysis of myenteric plexus and intestinal epithelium of colon in patients with Parkinson's disease.Acta neuropathologica communications · 2025Article
- α-1 antitrypsin is promising for the identification of glaucoma severity and is associated with glaucomatous neural damage.Biomarkers in medicine · 2024Article
- SerpinA1 levels in amyotrophic lateral sclerosis patients: An exploratory study.European journal of neurology · 2024Article
- Transcriptomics and Proteomics Approach for the Identification of Altered Blood microRNAs and Plasma Proteins in Parkinson's Disease.Cellular and molecular neurobiology · 2023Article
- Co-Expression Network Analysis Identifies Molecular Determinants of Loneliness Associated with Neuropsychiatric and Neurodegenerative Diseases.International journal of molecular sciences · 2023Article
- Multiregion transcriptomic profiling of the primate brain reveals signatures of aging and the social environment.Nature neuroscience · 2022Article
- Constitutive nuclear accumulation of endogenous alpha-synuclein in mice causes motor impairment and cortical dysfunction, independent of protein aggregation.Human molecular genetics · 2022Article
- Specific Cerebrospinal Fluid SerpinA1 Isoform Pattern in Alzheimer's Disease.International journal of molecular sciences · 2022Article
- CSF SerpinA1 in Creutzfeldt-Jakob disease and frontotemporal lobar degeneration.Annals of clinical and translational neurology · 2020Article
- Article
- Biomarkers for Dementia, Fatigue, and Depression in Parkinson's Disease.Frontiers in neurology · 2019Review
- Genetics of early-onset Parkinson's disease in Finland: exome sequencing and genome-wide association study.Neurobiology of aging · 2017Article
- Accuracy Improvement for Predicting Parkinson's Disease Progression.Scientific reports · 2016Article
- Naturally Occurring Autoantibodies against Tau Protein Are Reduced in Parkinson's Disease Dementia.PloS one · 2016Article
- Mass spectrometry methods for analysis of extracellular matrix components in neurological diseases.Mass spectrometry reviewsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early detection of dementia in Parkinson disease is a prerequisite for preventive therapeutic approaches. Modified serpinA1 in cerebrospinal fluid (CSF) was suggested as an early biomarker for differentiation between Parkinson patients with (PDD) or without dementia (PD). Within this study we aimed to further explore the diagnostic value of serpinA1. We applied a newly developed nanoscale method for the detection of serpinA1 based on automated capillary isoelectric focusing (CIEF). A clinical sample of 102 subjects including neurologically healthy controls (CON), PD and PDD patients was investigated. Seven serpinA1 isoforms of different charge were detected in CSF from all three diagnostic groups. The mean CSF signals of the most acidic serpinA1 isoform differed significantly (p < 0.01) between PDD (n = 29) and PD (n = 37) or CON (n = 36). Patients above the cut-off of 6.4 have a more than six times higher risk for an association with dementia compared to patients below the cut off. We propose this serpinA1 CIEF-immunoassay as a novel tool in predicting cognitive impairment in PD patients and therefore for patient stratification in therapeutic trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.